| abstract |
The present invention relates to the use of enantiomerically pure escitalopram and / or its low-dose drugs for improving the treatment of depression, especially serious depressive disorders, neurotic disorders, acute stress disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome cognitive disorders, impulsive disorders, attention-deficit hyperactivity or substance abuse. These drugs can also be used to treat serious depressive disorders in patients who are "resistant to treatment." The international application was published along with an international search report. |